Cargando…
Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
INTRODUCTION: Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway. METHODS: We summarize the available phase...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574739/ https://www.ncbi.nlm.nih.gov/pubmed/28639011 http://dx.doi.org/10.1007/s13555-017-0187-0 |
_version_ | 1783259897880641536 |
---|---|
author | Nakamura, Mio Lee, Katherine Jeon, Caleb Sekhon, Sahil Afifi, Ladan Yan, Di Lee, Kristina Bhutani, Tina |
author_facet | Nakamura, Mio Lee, Katherine Jeon, Caleb Sekhon, Sahil Afifi, Ladan Yan, Di Lee, Kristina Bhutani, Tina |
author_sort | Nakamura, Mio |
collection | PubMed |
description | INTRODUCTION: Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway. METHODS: We summarize the available phase III results to date, establishing the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis. RESULTS: Currently, there are available data of up to 48 weeks from two Phase III, multicenter, randomized, double-blind, placebo- and comparator-controlled clinical trials, VOYAGE 1 and VOYAGE 2. At week 16, the proportion of patients attaining at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) was 73.3% in VOYAGE 1 and 70.0% in VOYAGE 2. Guselkumab remained efficacious through 48 weeks of treatment. Guselkumab maintained a satisfactory safety profile with the most frequently reported adverse events being nasopharyngitis, headache, and upper respiratory tract infection. CONCLUSION: Phase III trials of Guselkumab suggest a favorable efficacy and safety profile of this novel drug. Although further studies are needed to assess long-term safety and efficacy, based on the results to date, guselkumab appears to be a promising therapeutic option for moderate-to-severe plaque-type psoriasis. |
format | Online Article Text |
id | pubmed-5574739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-55747392017-09-15 Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials Nakamura, Mio Lee, Katherine Jeon, Caleb Sekhon, Sahil Afifi, Ladan Yan, Di Lee, Kristina Bhutani, Tina Dermatol Ther (Heidelb) Review INTRODUCTION: Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway. METHODS: We summarize the available phase III results to date, establishing the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis. RESULTS: Currently, there are available data of up to 48 weeks from two Phase III, multicenter, randomized, double-blind, placebo- and comparator-controlled clinical trials, VOYAGE 1 and VOYAGE 2. At week 16, the proportion of patients attaining at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) was 73.3% in VOYAGE 1 and 70.0% in VOYAGE 2. Guselkumab remained efficacious through 48 weeks of treatment. Guselkumab maintained a satisfactory safety profile with the most frequently reported adverse events being nasopharyngitis, headache, and upper respiratory tract infection. CONCLUSION: Phase III trials of Guselkumab suggest a favorable efficacy and safety profile of this novel drug. Although further studies are needed to assess long-term safety and efficacy, based on the results to date, guselkumab appears to be a promising therapeutic option for moderate-to-severe plaque-type psoriasis. Springer Healthcare 2017-06-21 /pmc/articles/PMC5574739/ /pubmed/28639011 http://dx.doi.org/10.1007/s13555-017-0187-0 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Nakamura, Mio Lee, Katherine Jeon, Caleb Sekhon, Sahil Afifi, Ladan Yan, Di Lee, Kristina Bhutani, Tina Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials |
title | Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials |
title_full | Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials |
title_fullStr | Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials |
title_full_unstemmed | Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials |
title_short | Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials |
title_sort | guselkumab for the treatment of psoriasis: a review of phase iii trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574739/ https://www.ncbi.nlm.nih.gov/pubmed/28639011 http://dx.doi.org/10.1007/s13555-017-0187-0 |
work_keys_str_mv | AT nakamuramio guselkumabforthetreatmentofpsoriasisareviewofphaseiiitrials AT leekatherine guselkumabforthetreatmentofpsoriasisareviewofphaseiiitrials AT jeoncaleb guselkumabforthetreatmentofpsoriasisareviewofphaseiiitrials AT sekhonsahil guselkumabforthetreatmentofpsoriasisareviewofphaseiiitrials AT afifiladan guselkumabforthetreatmentofpsoriasisareviewofphaseiiitrials AT yandi guselkumabforthetreatmentofpsoriasisareviewofphaseiiitrials AT leekristina guselkumabforthetreatmentofpsoriasisareviewofphaseiiitrials AT bhutanitina guselkumabforthetreatmentofpsoriasisareviewofphaseiiitrials |